R1 Therapeutics Raises $77.5M in Series A to Advance Kidney Disease Therapeutics

R1 Therapeutics steps into the arena like it already knows where the pressure points are, and more importantly, how to press them. No theatrics, just $77.5M in an oversubscribed Series A and a strategy that reads like it was workshopped inside the problem, not outside of it.

Let’s talk about the signal inside that noise. Krishna Polu, M.D., Co-Founder, President and CEO, and L. Mary Smith, Ph.D., Co-Founder and COO, did not just raise capital, they aligned it. Abingworth, DaVita Venture Group, and F-Prime co-leading, with Curie.Bio, SymBiosis, and U.S. Renal Care stepping in. That is not a cap table, that is a map of influence across biotech and dialysis care. When your investors already live inside the problem, you are not guessing your way to product market fit, you are engineering it with people who have seen the edges of failure up close.

And the problem is not subtle. Hyperphosphatemia in chronic kidney disease patients on dialysis is one of those clinical realities that hides in plain sight. Common, dangerous, and stubborn. Current approaches lean on phosphate binders, which can feel like bringing a sponge to a flood. R1 Therapeutics is betting on something cleaner, more direct. AP306, a first-in-class pan phosphate transporter inhibitor, goes after active phosphate transport itself, targeting NaPi-IIb, PiT-1, and PiT-2. Less binding, more blocking. Less chasing symptoms, more stepping into the mechanism.

The Alebund Pharmaceuticals collaboration tightens the story. Exclusive rights outside Greater China, Alebund holding ground within it, and a planned global Phase 2b trial bridging the U.S. and China. That is how you turn geography into strategy instead of friction. Two companies, 1 molecule, shared urgency, and no patience for incremental progress dressed up as innovation.

There is a rhythm to this kind of build. Start with a molecule that already showed Phase 2 data. Surround it with capital that understands the patient journey. Place it in the hands of operators who have seen this movie before and decided they did not like the ending. Then move fast, but not sloppy. Precision over noise, always.

The takeaway for anyone building is simple, but not easy. Proximity matters. R1 Therapeutics did not just raise money, they raised context. They did not just license a drug, they licensed a real shot at redefining how phosphate is controlled in a population that has been managing trade-offs for too long.